Premium
Causes of early death and treatment‐related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group
Author(s) -
Klein Kim,
Litsenburg Raphaële R.L.,
Haas Valérie,
Dors Natasja,
den HeuvelEibrink Marry M.,
Knops Rutger R.G.,
Tissing Wim J.E.,
Versluys Birgitta A.,
Zwaan C. Michel,
Kaspers Gertjan J.L.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28099
Subject(s) - medicine , cumulative incidence , incidence (geometry) , myeloid leukemia , pediatrics , leukemia , oncology , cohort , physics , optics
Abstract Background With the current more effective treatment regimens for pediatric acute myeloid leukemia (AML), research on early death (ED), treatment‐related mortality (TRM), and toxicity becomes increasingly important. The aim of this study was to give an overview of the frequency, clinical features, and risk factors associated with ED and TRM in first complete remission (CR1) during the last three consecutive treatment protocols of the Dutch Childhood Oncology Group (DCOG) between 1998 and 2014. Methods Incidence and risk factors associated with ED and TRM in CR1 were retrospectively studied in 245 patients treated according to the Dutch ANLL‐97/AML‐12 ( n = 118), AML‐15 ( n = 60), or DB AML‐01 ( n = 67) protocols. Results The incidence of ED was, respectively, 5.1%, 6.7%, and 3.0% excluding deaths before treatment ( P = NS), and 7.4%, 11.1%, and 4.4% including deaths before the onset of treatment. Severe underweight at initial diagnosis was significantly associated with more frequent ED. When relapse was included as a competing risk, cumulative incidence of death in CR1 were 5.9%, 5.0%, and 4.6% for ANLL97, AML15, and DB01, respectively ( P = NS). The most important cause of TRM included infectious and SCT‐related complications. Conclusion We report relatively stable rates of ED and TRM in CR1 in the latest completed DCOG protocols for newly diagnosed AML patients. The most important causes of TRM were SCT‐ or infection‐related, warranting further evaluation and awareness.